ACTION receives $2 million grant from Parent Project Muscular Dystrophy (PPMD) to expand muscular dystrophy focused research and quality improvement initiatives
ACTION centers collaborate with Abbott to update FDA labeling of the HeartMate 3™ LVAD for use in pediatrics CINCINNATI — The FDA has updated Abbott’s HeartMate 3™ LVAD labeling to treat children with heart failure. Collaborating with Abbott, ACTION’s clinicians, researchers, parents and patients from over 50 medical institutions provided high-quality, real-world retrospective data to accelerate the
This multicenter analysis shows bivalirudin is an effective alternative to heparin for anticoagulation in pediatric mechanical circulatory support, with comparable bleeding and stroke outcomes.
See Humera Ahmed, MD’s Oral Presentation.
See Paul Devlin, MD, MSc’s Oral Presentation.
See Tammy Ruth, MD’s Oral Presentation.
See Bhavikkumar Langanecha, MD’s Poster Presentation.
See Deepa Mokshagundam, MD’s Oral Presentation.
